The Pluripotency Factor Musashi-2 Is a Novel Target for Lung Cancer Therapy
Mary R. Zhang(National Cancer Institute), David S. Schrump(National Institutes of Health), Yin Xiong(Wenzhou Medical University), Chuong D. Hoang(National Institutes of Health), Haobin Chen(Washington University in St. Louis), Vivek Shukla(National Institutes of Health), R. Taylor Ripley, Sichuan Xi(National Cancer Center), Julie A. Hong(National Institutes of Health)
Cited by 7
Related Papers
Adenovirus-Mediated p53 Gene Transfer in Advanced Non-Small-Cell Lung Cancer
|JNCI Journal of the National Cancer Institute|1999|497
Database Resources of the National Genomics Data Center, China National Center for Bioinformation in 2025
|Nucleic Acids Research|2024|362
Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer
|Cell Reports Medicine|2020|186
Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors
|Journal of Clinical Oncology|2017|177
Modulation of histone methylation and MLH1 gene silencing by hexavalent chromium
|Toxicology and Applied Pharmacology|2009|166